• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

There's a Play to Be Had With Pfizer

Getting dropped from the Dow may give PFE the catalyst it needs to make a big move one way or the other.
By TIMOTHY COLLINS
Aug 25, 2020 | 02:19 PM EDT
Stocks quotes in this article: FB, PFE, XOM, RTX

Following the Dow and its additions and subtractions is akin to Facebook (FB) stalking your significant other from the tenth grade. Maybe you have a few moments of nostalgia, but the importance and notice of what you see now fades quickly. That's how it will be in a week or two from now with Pfizer (PFE) , Exxon Mobil (XOM) , and Raytheon (RTX) . Heck, Raytheon was in for such a short time some may not even realize it has come and gone.

I haven't done enough digging into whether leaving the Dow is a blessing and being added a curse, so I won't opine on the ousters should be added or the newcomers sold, but this move may give Pfizer the catalyst it needs to make a big move one way or the other.

The stock has been consolidating for weeks now. We have multiple patterns and indicators suggesting volatility is on the horizon, so straddle and strangle players may want to give this one consideration for an October, or possibly even a September, expiration. If we examine the weekly chart, we see a strong W-shaped price pattern with the right low being higher than the left low. This is often indicative of a strong, bullish setup. The stock demonstrates more of a double-top rather than a triple top as the middle of the W fell short of the current resistance line.

Although the price pattern is strong, there are some concerns with the underlying indicators. The Full Stochastics indicator has hit an overbought position. The good news is overbought can remain overbought, but when this has turned over (bearish crossover), Pfizer stock has fallen hard. The same is true with the Stochastics RSI as well as the parabolic stop-and-reverse (PSAR). The good news is NONE of these have yet triggered bearish, but investors and traders should keep a very close eye on the setup.

A weekly close above $39.50 should send Pfizer into breakout mode into the $44-$45 range within two months. Unfortunately, if those secondary indicators fail and rollover, I would expect a drop in the 10% to 15% range, so certainly not a small pullback, and one that could trap Pfizer in the $30s well into 2021.

We know getting dropped from the Dow isn't the kiss of death. The index is not nearly as active as the S&P 500 or the Nasdaq 100 in terms of underlying ETFs, hedges, or even basic allocation. Among many traders, it's a running joke of an index and what it represents. That being said, the headlines will likely be enough to draw extra trader scrutiny over the next few weeks. This extra attention should be enough of a catalyst to put the bullish or bearish outcome into play. In other words, I believe a trader could either take a long volatility position, like buying an October $38 straddle, now, or wait for one of the breakouts to trigger, then play the stock either higher or lower (depending on the breakout).

Either way, there's a play to be had now or one I believe coming soon. Keep Pfizer on your list as a somewhat of a sleep stock that may be about to become very interesting.

(Facebook is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells FB? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins had no position in the securities mentioned.

TAGS: Investing | Markets | Stocks | Technical Analysis | Trading | Healthcare

More from Investing

I Got the 'SOS', So Here's My Take on the Stock's Saga

Timothy Collins
Feb 28, 2021 6:35 PM EST

Let's try to sort out the details of the complicated story of SOS Ltd. -- and why the short reports might be ... selling you short.

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Bob Lang
Feb 28, 2021 10:30 AM EST

These names are displaying both quantitative and technical deterioration.

Jim Cramer: What History Tells Us About Bond-Rate Scares Like This

Jim Cramer
Feb 27, 2021 2:01 PM EST

We could have some real pain ahead for some stocks. Five different kinds.

What's Next for Bonds, TLT and Interest Rates?

Bruce Kamich
Feb 27, 2021 12:30 PM EST

Thoughts and observations on Treasuries and the direction of interest rates.

Navigating a Market Correction

James "Rev Shark" DePorre
Feb 27, 2021 10:00 AM EST

The most critical factor in long-term market success is the ability to effectively navigate market corrections.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login